EGFR and squamous cell carcinoma: When the folate moiety was replaced with anti-EGFR nanobody, the anticancer activity of ClyA nanobody increased compared to low-cysteine ClyA (the IC50 values of 7.2 and 17.1 nM, respectively, against A431 epidermoid carcinoma cells overexpressing EGFR).